DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
STRATEC completes acquisition of Sony DADC BioSciences
Birkenfeld, July 1, 2016
STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) today announces the successful completion of the acquisition of Sony DADC BioSciences GmbH ('BioSciences'), a leading global OEM supplier of smart consumables for diagnostics, life sciences and medical technology applications.
On June 8, 2016, STRATEC announced that it signed an agreement with Sony DADC Austria AG ('Sony DADC'), based in Anif/Salzburg, Austria, to acquire all of the shares of BioSciences, a wholly-owned subsidiary of Sony DADC.
The joining of these companies will enlarge STRATEC's capabilities to serve its customers, by combining macro-and microfluidic solutions as well as offering services spanning sample preparation solutions, software, instrument automation and polymer consumables development and manufacturing. The acquisition diversifies STRATEC's overall customer structure and extends the value chain significantly.
Going forward, the business will operate under the name of STRATEC Consumables.
The consolidation will start with July, 1, 2016.
The partners market the systems, software and consumables in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from: